Hints and tips:
Related Special Reports
...The other big vaccine makers, including Sanofi and GSK, are now working on mRNA....
...Both Sanofi and Novavax previously committed to orders with the EU that were much smaller than the headline numbers announced, people familiar with the matter said....
...Horizon had also attracted interest from French drugmaker Sanofi and US pharma group Johnson & Johnson....
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...Earlier on Monday, French pharmaceutical company Sanofi struck a deal to buy Type-1 diabetes treatment developer Provention Bio for $2.9bn, in a bid to bolster its drug pipeline after facing pressure from...
...Details of a draft deal reported by the FT suggest that BioNTech/Pfizer could supply as many as 70mn doses a year until 2026, leaving little room for Novavax, Moderna or Sanofi....
...Novavax’s Stanley Erck will be replaced by John C Jacobs, most recently chief executive at Harmony Biosciences, this month; CureVac’s Franz-Werner Haas will be succeeded by Alexander Zehnder, a Sanofi veteran...
...To beat out Johnson & Johnson and Sanofi, Amgen will be paying nearly 45 times EV to ebitda for Horizon. The wider S&P Biotech index trades on a multiple of 11.4 times....
...Horizon said last month that it was in takeover talks with three potential suitors, among them Johnson & Johnson and Sanofi....
...Horizon’s assets, which include treatments for chronic gout and neuromyelitis optica, a disease affecting the central nervous system, had also attracted interest from Johnson & Johnson and Sanofi....
...Lex) Washington Post considers selling tech business It built up on Jeff Bezos’s watch (Wall Street Journal) Mining magnate Andrew Forrest becomes Australia’s largest renewables player (FT) GSK and Sanofi...
...New entrants Novavax and Sanofi/GSK, the latter of which aims to get their Covid jab approved this year, will struggle to gain market share as Covid becomes endemic and public apathy to getting inoculated...
...Sanofi predicts it could be even bigger, hitting $17bn by 2030....
...SeaGen also recently signed a partnership with French drugmaker Sanofi and has agreements with Takeda and Bristol Myers Squibb among others. SeaGen declined to comment....
...In June, Sanofi and GSK reported promising results from trials of their Covid vaccine, which they said had proved effective against the Omicron strain of coronavirus....
...In later-stage phase 3 trial results published in September, the Novavax flu vaccine had comparable results to the Sanofi flu shot....
...Another French effort came to nothing in January when a Covid-19 vaccine out of the Pasteur Institute, which was later licensed to Merck, also failed in clinical trials....
...The world’s biggest vaccine makers GlaxoSmithKline, Merck and Sanofi have all failed to deliver Covid jabs at all....
...Angus Thomson, former head of vaccine confidence and coverage at French pharmaceuticals group Sanofi Pasteur, said France’s passport scheme helped jolt “wait-and-see-ers” into action....
...The delay means Sanofi is unlikely to be able to bring a vaccine to market until the end of this year at the earliest....
...He noted it was adding capacity to fill vials with its recent agreement with Sanofi Pasteur....
...GSK, Merck and Sanofi shares have fallen between 13 and 30 per cent....
...Sanofi and GSK The large vaccine manufacturers Sanofi and GSK, despite failing to keep up with likes of Pfizer last year, are also expected to play an important role supplying middle- and lower-income countries...
...“As we move into the next couple of years there’s a whole wave of vaccines that are likely going to be approved — GSK, Sanofi, and a lot of other players,” Conover said, noting that Pfizer will struggle...
...France’s prestigious Institut Pasteur abandoned its project while Sanofi’s has been delayed. Valneva, a Franco-Austrian biotech, will make its vaccine in Scotland....
International Edition